The conversation is about skepticism towards a hair growth oil promoted by a social media influencer, with users suggesting it is ineffective without proven treatments like Minoxidil, finasteride, or hair transplants. The product contains various oils and extracts, but users doubt its effectiveness.
The post is about a user starting a hair loss treatment using finasteride, micro needling, and nizoral. The conversation includes supportive replies from other users.
Researchers are working on regenerating hair follicles using stem cells, but a cure for baldness is still years away. Current treatments mentioned include Minoxidil, finasteride, and RU58841.
Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.
Use a stamp or roller for microneedling; stamps are preferred to avoid hair pulling. Clean tools with alcohol to prevent infection, and replace stamps every 4-6 uses.
The user is experiencing a burning sensation on their scalp despite using finasteride and nizoral for hair loss, and is unsure if they should switch to dutasteride. They have reduced their testosterone dose but the burning persists, and a trichologist suggested it might be telogen effluvium.
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.
The struggles of hair loss at a young age and available treatments, such as medication (Finasteride, Minoxidil, Dutasteride, Derma Rolling) and potential options for hair systems or cloning in Japan. People discussed their own experiences with trying to cope with the emotional aspects of this condition.
Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
Balding is challenging, and relying on medications like finasteride is often seen as a better option than constantly shaving or trying to compensate in other areas. Many feel that societal expectations to "own it" or drastically change oneself to cope with baldness are unrealistic and burdensome.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
The conclusion of this conversation about hair loss is that genetics play a significant role in determining hair loss, and specific treatments like finasteride may not be effective against certain compounds like masteron and trenbolone.
Hair loss discussion with a focus on a single resilient hair, jokingly called "chad hair," that remains despite hairline receding. Some users suggest microneedling and hair follicle cloning as potential treatments.
The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.
The user experienced excessive bleeding during microneedling after consuming caffeine and THC, and is unsure if they should continue with the same routine. They are seeking advice on whether the bleeding is a cause for concern.
User questions credibility of a hair loss "cure" found by a non-expert and warns against wasting money on unproven supplements. Others discuss trying natural extracts and the importance of researching the enzyme 3ADH for potential hair growth benefits.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.
Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.
The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.
A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
The conversation discusses a shared PDF about hair loss treatments, which might help those not seeing results with Minoxidil, Finasteride, and RU58841. Some users are skeptical about the content's value and the price charged for it.
Sons offers free Biotin capsules, Thickening Clay, or Conditioner to UK men for hair care testing. Interested individuals can apply online to receive these products.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.